Triple-negative breast cancer remains one of oncology's most frustrating challenges precisely because it lacks the molecular handles — hormone receptors, HER2 — that targeted therapies exploit in other breast cancers. Understanding how TNBC rewires its local immune environment to escape destruction is therefore a high-priority question, and this research points to a metabolic-epigenetic axis that could eventually reshape therapeutic strategy.
The study identifies phosphoglycerate kinase 1 (PGK1), a glycolytic enzyme, as a key driver of histone lactylation — a post-translational modification in which lactate groups are added to histone proteins, altering gene expression — within the TNBC tumor microenvironment. This PGK1-mediated lactylation was found to expand myeloid-derived suppressor cells (MDSCs), a heterogeneous immune cell population well-established for dampening anti-tumor T-cell responses. By epigenetically reprogramming these suppressive myeloid cells, PGK1 activity creates an immunosuppressive niche that enables tumor progression to proceed with reduced immune surveillance.
Histone lactylation itself is a relatively recent discovery — first described in 2019 — and the field is still mapping which cellular contexts it governs. What makes this finding analytically interesting is the mechanistic specificity: rather than lactate acting diffusely, a single glycolytic enzyme appears to be directing the epigenetic modification that arms MDSCs. This implies a potential druggable node. PGK1 inhibitors exist in preclinical development, and if this mechanism holds across broader TNBC cohorts, they could be repositioned as immunometabolic agents rather than pure metabolic blockers. The critical caveat is that the current evidence base — at least as published — has not yet been characterized against large human cohorts or randomized intervention models. This is mechanistic science, likely anchored in cell-line and mouse data, and the translational distance to clinical application remains substantial. Still, as an addition to the growing literature connecting the Warburg effect to immune evasion via epigenetic intermediaries, this represents a meaningful conceptual advance.